Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

PURPOSE: Biliary cancers overexpress epidermal growth factor receptor (EGFR), and angiogenesis has been correlated with poor outcome. Erlotinib, an EGFR tyrosine kinase inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor have each been shown to have activity in biliary...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Lubner, Sam J., Mahoney, Michelle R., Kolesar, Jill L., LoConte, Noelle K., Kim, George P., Pitot, Henry C., Philip, Philip A., Picus, Joel, Yong, Wei-Peng, Horvath, Lisa, Van Hazel, Guy, Erlichman, Charles E., Holen, Kyle D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2010
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917213/
https://ncbi.nlm.nih.gov/pubmed/20530271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.4075
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia